Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:03:56 2023-02-07 pm EST
111.99 USD   +1.12%
01/26Raymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outperform Rating
MT
01/26Abbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neuropathy
MT
01/26Abbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)

10/21/2022 | 04:07pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers



As previously reported, Abbott has Agreements Regarding Change in Control ("Agreements") with its named executive officers.

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2022), the Agreement's term shall continue through the second anniversary of the Expiration Date.

On October 18, 2022, Abbott notified the named executive officers that the term of the Agreements was extended through December 31, 2024.

© Edgar Online, source Glimpses

All news about ABBOTT LABORATORIES
01/26Raymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outper..
MT
01/26Abbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neu..
MT
01/26Abbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
01/26Bernstein Adjusts Price Target on Abbott Laboratories to $132 From $125, Maintains Outp..
MT
01/26FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic P..
PR
01/26Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Procla..
CI
01/26Jefferies Adjusts Price Target on Abbott Laboratories to $112 From $105, Maintains Hold..
MT
01/26Barclays Adjusts Price Target on Abbott Laboratories to $125 From $122, Maintains Overw..
MT
01/26Stifel Adjusts Price Target on Abbott Laboratories to $125 From $110, Maintains Buy Rat..
MT
01/26Wolfe Research Adjusts Price Target on Abbott Laboratories to $107 From $92, Maintains ..
MT
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 43 227 M - -
Net income 2022 6 848 M - -
Net Debt 2022 4 567 M - -
P/E ratio 2022 28,3x
Yield 2022 1,66%
Capitalization 195 B 195 B -
EV / Sales 2022 4,62x
EV / Sales 2023 4,93x
Nbr of Employees 113 000
Free-Float 87,2%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 110,75 $
Average target price 120,97 $
Spread / Average Target 9,23%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES1.82%193 101
MEDTRONIC PLC12.07%113 385
BECTON, DICKINSON AND COMPANY-1.63%71 021
DEXCOM, INC.-5.75%41 225
HOYA CORPORATION12.04%38 235
SARTORIUS STEDIM BIOTECH16.69%34 935